The IsoLight is a first-of-its-kind system for high-throughput, single-cell functional proteomic detection
BRANFORD, Conn., July 24, 2018 /PRNewswire/ — IsoPlexis Corporation (IsoPlexis), a privately held life sciences company at the forefront of single-cell analytics technology, has installed its ground-breaking IsoLight benchtop system at Fred Hutchinson Cancer Research Center, as part of the company’s Early Adopter Program.
The sample-to-answer IsoLight benchtop system analyzes IsoPlexis’ IsoCode chip, to provide clinical and translational researchers a powerful, yet straightforward solution for establishing immune response functional correlates with outcome in key therapeutic areas like CAR-T and other cellular immunotherapies. The IsoCode Chip was recognized as The Scientist’s and Fierce Life Science’s #1 innovation of 2017 for its ability to provide both single-cell sensitivity and highly multiplexed and quantitative functional ELISA detection together for the first time.
Sean Mackay, CEO and Co-founder of IsoPlexis, commented “We are very excited to be placing an IsoLight system at Fred Hutch, a pioneer in CAR-T immunotherapy. We strive to provide the benefits of high dimensional, single-cell proteomic data to partners like Fred Hutch, in order to continue to improve cellular characterization and correlates in the fast-moving immuno-oncology field and beyond.”
Data from the IsoCode Chip was recently published in the journal Blood, showing improved ability to predict responses of CAR-T patients pre-infusion, versus existing technologies. The IsoLight, which was awarded global Red Dot Design Award in 2018, has an integrated design combining precision imaging and fluidics with a user-friendly software interface to create a uniquely easy-to-use single-cell system.
For more information about the IsoLight, please visit http://www.isoplexis.com/products.
ABOUT ISOPLEXIS:
IsoPlexis, a privately held life sciences company, is developing novel technologies at the forefront of the revolution in immunity-based treatments of cancer. Using a next-generation diagnostic and therapeutic platform to identify patient responses at the single cell level, IsoPlexis’ original scientific leaders from Yale, Caltech, UCLA, and Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures and Connecticut Innovations, as well as supported through grant funding from the National Cancer Institute and the National Institutes of Health. For additional information on IsoPlexis, visit http://www.isoplexis.com or email info@isoplexis.com.
MEDIA CONTACT:
Jon Chen
Director of Demand Generation
Telephone: 475.221.8285
jon@isoplexis.com